PI3K/AKT signaling pathway and cancer: an updated review

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Targeted therapies require precise matching to individual tumor genetic profiles for efficacy.
• Gain-of-function mutations in phosphoinositide 3-kinases (PI3Ks) are frequently observed in various cancers.
• PI3K signaling is a critical pathway activated by receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCRs), leading to cell proliferation and survival via AKT and mTOR.

Purpose of the Study:

• To investigate the role of class I PI3K catalytic subunit mutations (p110α, β, γ, δ) in AKT-mediated cellular processes relevant to tumor development.
• To explore the interconnectedness of the PI3K signaling pathway with other key oncogenic pathways, including mTOR, ERK, and RAS.
• To evaluate the therapeutic potential of PI3K signaling inhibitors in clinical oncology.

Main Methods:

• Analysis of genetic alterations and mutational profiles in tumor samples.
• Elucidation of signaling pathway interactions using molecular biology techniques.
• Review of existing literature and clinical data on PI3K signaling inhibitors.

Main Results:

• Class I PI3K catalytic subunit mutations significantly influence AKT-mediated cellular functions critical for tumorigenesis.
• The PI3K pathway exhibits complex interrelations with mTOR, ERK, and RAS signaling networks.
• PI3K pathway dysregulation is a common feature across diverse tumor types, highlighting its oncogenic importance.

Conclusions:

• Understanding PI3K mutations is crucial for developing effective targeted cancer therapies.
• Inhibitors targeting the PI3K pathway hold significant promise for improving treatment outcomes and reducing side effects.
• Further research into PI3K pathway modulation could lead to novel therapeutic strategies for various malignancies.